Zhang Zhuo, Li Mao, Rayburn Elizabeth R, Hill Donald L, Zhang Ruiwen, Wang Hui
Department of Pharmacology and Toxicology and Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA.
Am J Pharmacogenomics. 2005;5(5):327-38. doi: 10.2165/00129785-200505050-00005.
This is the third paper in a four-part serial review on potential therapeutic targeting of oncogenes. The previous parts described the involvement of oncogenes in different aspects of cancer growth and development, and considered the new technologies responsible for the advancement of oncogene identification, target validation, and drug design. Because of such advances, new specific and more efficient therapeutic agents can be developed for cancer. This part of the review continues the exploration of various oncogenes that we have grouped within seven categories: growth factors, tyrosine kinases, intermediate signaling molecules, transcription factors, cell cycle regulators, DNA damage repair genes, and genes involved in apoptosis. Part one discussed growth factors and tyrosine kinases and part two discussed intermediate signaling molecules. This portion of the review covers transcription factors and the various strategies being used to inhibit their expression or decrease their activities.
这是一篇关于癌基因潜在治疗靶点的四部分系列综述中的第三篇论文。前几部分描述了癌基因在癌症生长和发展的不同方面的作用,并探讨了推动癌基因识别、靶点验证和药物设计进步的新技术。由于这些进展,可以开发出针对癌症的新型特异性和更高效的治疗药物。本部分综述继续探索我们归为七类的各种癌基因:生长因子、酪氨酸激酶、中间信号分子、转录因子、细胞周期调节因子、DNA损伤修复基因以及参与细胞凋亡的基因。第一部分讨论了生长因子和酪氨酸激酶,第二部分讨论了中间信号分子。本部分综述涵盖转录因子以及用于抑制其表达或降低其活性的各种策略。